Literature DB >> 25686117

Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.

Yoshimitsu Kobayashi1, Yoshito Komatsu, Satoshi Yuki, Hiraku Fukushima, Takahide Sasaki, Ichiro Iwanaga, Minoru Uebayashi, Hiroyuki Okuda, Takaya Kusumi, Takuto Miyagishima, Susumu Sogabe, Miki Tateyama, Kazuteru Hatanaka, Yasushi Tsuji, Michio Nakamura, Jun Konno, Fumiyasu Yamamoto, Manabu Onodera, Kazuhiro Iwai, Yuh Sakata, Riichiro Abe, Koji Oba, Naoya Sakamoto.   

Abstract

AIM: We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin toxicities in Japanese patients with metastatic colorectal cancer. PATIENTS &
METHODS: Patients receiving third-line Pmab-containing regimens were randomized to pre-emptive or reactive treatment. The primary end point was the cumulative incidence of ≥grade 2 skin toxicities during 6 weeks. Retrospectively, a dermatologist reviewed skin toxicities, in a blinded manner.
RESULTS: A total of 95 patients were enrolled (pre-emptive: 47, reactive: 48). The primary end point was achieved (21.3 and 62.5% [risk ratio: 0.34; p < 0.001], for pre-emptive and reactive treatment, respectively). A similar trend was observed in central review.
CONCLUSION: Pre-emptive skin treatment could reduce the severity of Pmab-associated skin toxicities in Japanese metastatic colorectal cancer patients.

Entities:  

Keywords:  Japanese; colorectal cancer; panitumumab; pre-emptive; skin toxicities

Mesh：

Substances：

Year:  2015        PMID： 25686117     DOI： 10.2217/fon.14.251

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  18 in total

1.  Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).

Authors:  Yohei Iimura; Naoki Furukawa; Masaaki Ishibashi; Yuka Ahiko; Taro Tanabe; Susumu Aikou; Dai Shida; Masanori Nojima; Seiichiro Kuroda; Narikazu Boku
Journal:  BMC Gastroenterol       Date:  2022-07-14       Impact factor: 2.847

2.  Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study).

Authors:  Tomohiro Nishi; Yasuo Hamamoto; Michitaka Nagase; Tadamichi Denda; Kensei Yamaguchi; Kenji Amagai; Yoshinori Miyata; Yasuhiro Yamanaka; Kai Yanai; Tsutomu Ishikawa; Yoshifumi Kuroki; Hirofumi Fujii
Journal:  Oncol Lett       Date:  2016-05-06       Impact factor: 2.967

3.  Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study).

Authors:  Masahiro Iwasaku; Junji Uchino; Tadaaki Yamada; Yusuke Chihara; Takayuki Shimamoto; Nobuyo Tamiya; Yoshiko Kaneko; Fumiaki Kiyomi; Koichi Takayama
Journal:  Transl Lung Cancer Res       Date:  2019-08

4.  AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer.

Authors:  Melanie Kripp; Nicole Prasnikar; Ursula Vehling-Kaiser; Julia Quidde; Salah-Eddin Al-Batran; Alexander Stein; Kai Neben; Carla Verena Hannig; Hans Werner Tessen; Tanja Trarbach; Axel Hinke; Ralf-Dieter Hofheinz
Journal:  Oncotarget       Date:  2017-09-23

5.  Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management.

Authors:  Shoichi Watanabe; Motoki Nakamura; Hiroki Takahashi; Masayasu Hara; Kei Ijichi; Daisuke Kawakita; Akimichi Morita
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-09-11

6.  Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).

Authors:  Kazumi Nishino; Yutaka Fujiwara; Yuichiro Ohe; Ryota Saito; Eisaku Miyauchi; Tetsu Kobayashi; Yasuo Nakai; Toshiaki Takahashi; Taro Shibata; Tetsuya Hamaguchi; Katsuko Kikuchi; Naoya Yamazaki; Haruhiko Fukuda; Keiko Nozawa; Yoshio Kiyohara
Journal:  Support Care Cancer       Date:  2020-09-11       Impact factor: 3.603

Review 7.  Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.

Authors:  Ralf-Dieter Hofheinz; Gaël Deplanque; Yoshito Komatsu; Yoshimitsu Kobayashi; Janja Ocvirk; Patrizia Racca; Silke Guenther; Jun Zhang; Mario E Lacouture; Aminah Jatoi
Journal:  Oncologist       Date:  2016-07-22

Review 8.  Role of targeted therapy in metastatic colorectal cancer.

Authors:  Yoshihito Ohhara; Naoki Fukuda; Satoshi Takeuchi; Rio Honma; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita
Journal:  World J Gastrointest Oncol       Date:  2016-09-15

9.  A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.

Authors:  Bernd Tischer; Martina Bilang; Matthias Kraemer; Philippe Ronga; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2017-11-07       Impact factor: 3.603

10.  A National Survey of Medical Oncologist's Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab.

Authors:  Kimberly A Lowe; Laura Sangaré; Rachel Bergstresser; Michelle McNamara; George Kafatos; Tamer Garawin
Journal:  Dermatol Ther (Heidelb)       Date:  2019-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.